PROCESS FOR THE PREPARATION OF TOLERIZING IMMUNE-MODULATING PARTICLES

(19)

(11)

EP 3 416 624 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	23.08.2023 Bulletin 2023/34

(45)	Mention of the grant of the patent:
	19.07.2023 Bulletin 2023/29

(21)	Application number: 17754041.6

(22)	Date of filing: 21.02.2017

(51)

International Patent Classification (IPC):

A61K 9/14^(2006.01)

A61K 9/51^(2006.01)

(52)	Cooperative Patent Classification (CPC):
	A61K 47/26; A61K 9/19; A61K 9/51; A61K 9/5146; A61K 9/5153; A61K 9/5192

(86)	International application number:
	PCT/US2017/018743

(87)	International publication number:
	WO 2017/143346 (24.08.2017 Gazette 2017/34)

(54)	PROCESS FOR THE PREPARATION OF TOLERIZING IMMUNE-MODULATING PARTICLES VERFAHREN ZUR HERSTELLUNG VON TOLERIERENDEN IMMUNMODULIERENDEN PARTIKELN PROCÉDÉ DE PRÉPARATION DE PARTICULES IMMUNOMODULATRICES INDUISANT UNE TOLÉRANCE

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

18.02.2016 US 201662296840 P

(43)	Date of publication of application:
	26.12.2018 Bulletin 2018/52

(60)	Divisional application:
	23185616.2

(73)	Proprietor: Cour Pharmaceuticals Development Company Inc.
	Skokie, IL 60077 (US)

(72)	Inventors:
	GETTS, Daniel R. Northbrook Illinois 60062 (US) FOKTA, Frank Northbrook Illinois 60062 (US) PEARSON, Ryan Northbrook Illinois 60062 (US)

(74)	Representative: CMS Cameron McKenna Nabarro Olswang LLP
	Cannon Place 78 Cannon Street London EC4N 6AF London EC4N 6AF (GB)

(56)

References cited: :

WO-A1-2014/169255
US-A- 4 574 058
US-A1- 2015 297 531

WO-A2-2015/023796
US-A1- 2015 010 631

JUNG, KA ET AL.: 'Cardiovascular Protective Properties of Kiwifruit Extracts in Vitro' BIOLOGICAL AND PHARMACEUTICAL BULLETIN vol. 28, no. 9, 2005, pages 1782 - 1785, XP009156175
KIM, S.: 'Production of composites by using gliadin as a bonding materia' JOURNAL OF CEREAL SCIENCE vol. 54, 2011, pages 168 - 172, XP028248398

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).